Development of an HTS Assay for the Search of Anti-influenza Agents Targeting the Interaction of Viral RNA with the NS1 Protein

Abstract

The NS1 protein is a nonstructural protein encoded by the influenza A virus. It is responsible for many alterations produced in the cellular metabolism upon infection by the virus and for modulation of virus virulence. The NS1 protein is able to perform a large variety of functions due to its ability to bind various types of RNA molecules, from both viral and nonviral origin, and to interact with several cell factors. With the aim of exploring whether the binding of NS1 protein to viral RNA (vRNA) could constitute a novel target for the search of anti-influenza drugs, a filter-binding assay measuring the specific interaction between the recombinant His-NS1 protein from influenza A virus and a radiolabeled model vRNA (³²P-vNSZ) was adapted to a format suitable for screening and easy automation. Flashplate^® technology (PerkinElmer, Waltham, MA), either in 96- or 384-well plates, was used. The Flashplate^® wells were precoated with the recombinant His-NS1 protein, and the binding of His-NS1 to a ³⁵S-vNSZ probe was measured. A pilot screening of a collection of 27,520 mixtures of synthetic chemical compounds was run for inhibitors of NS1 binding to vRNA. We found 3 compounds in which the inhibition of NS1 binding to vRNA, observed at submicromolar concentrations, was correlated with a reduction of the cytopathic effect during the infection of cell cultures with influenza virus. These results support the hypothesis that the binding of NS1 to vRNA could be a novel target for the development of anti-influenza drugs. ( Journal of Biomolecular Screening 2008:581-590)

Keywords

influenza viral RNA NS1 Flashplate

References

Stohr K. : Preventing and treating influenza. Br Med J 2003;326:1223-1224.

Kawaoka Y. , Krauss S. , Webster RG : Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989 ;63:4603-4608.

De Jong JC , Claas EC , Osterhaus AD , Webster RG , Lim WL : A pandemic warning ? Nature 1997;389:554.

Webby RJ , Webster RG : Are we ready for pandemic influenza? Science 2003;302:1519-1522.

Harper SA , Fukuda K. , Uyeki TM , Cox JJ , Bridges CB : Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom Rep 2004;53:1-40.

Hay AJ , Wolstenholme AJ , Skehel JJ , Smith MH : The molecular basis of the specific anti-influenza action of amantadine . EMBO J 1985;4:3021-3024.

Gubareva LV , Penn CR , Webster RG : Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1995;212:323-330.

Wu MJ , Ing TS , Soung LS , Daugirdas JT , Hano JE , Gandhi VC : Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 1982;17:19-23.

Van Voris LP , Betts RF , Hayden FG , Christmas WA , Douglas RG Jr : Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981;245:1128-1131.

10.

Cass LM , Efthymiopoulos C. , Bye A. : Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999;36(Suppl. 1):1-11.

11.

Hayden FG , Treanor JJ , Fritz RS , Lobo M. , Betts RF , Miller M. , et al: Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment . JAMA 1999;282:1240-1246.

12.

Monto AS , Arden NH : Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 1992;15:362-367.

13.

Hall CB , Dolin R. , Gala CL , Markovitz DM , Zhang YQ , Madore PH , et al: Children with influenza A infection: treatment with rimantadine . Pediatrics 1987;80:275-282.

14.

Kiso M. , Mitamura K. , Sakai-TagawaY. , Shiraishi K. , Kawakami C. , Kimura K. , et al: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-765.

15.

Toogood PL , Galliker PK , Glick GD , Knowles JR : Monovalent sialosides that bind tightly to influenza A virus. J Med Chem 1991;34:3138-3140.

16.

Choi SK , Mammen M. , Whitesides GM : Monomeric inhibitors of influenza neuraminidase enhance the hem agglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups . Chem Biol 1996;3:97-104.

17.

Parkes KE , Ermert P. , Fassler J. , Ives J. , Martin JA , Merrett JH , et al: Use of a pharmacophore mode to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003;46:1153-1164.

18.

Tomassini JE , Selnick H. , Davies ME , Armstrong ME , Baldwin J. , Bourgeois M. , et al: Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2.4-dioxobutanoid acid compounds . Antimicrob Agents Chemother 1994;38:2827-2837.

19.

Tomassini JE , Davies ME , Hastings JC , Lingham R. , Mojena M. , Raghoobar SL , et al: A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother 1996;40:1189-1193.

20.

Klumpp K. , Hang JQ , Rajendran S. , Yang Y. , Derosier A. , Wong Kai In P. , et al: Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 2003;31:6852-6859.

21.

Katze MG , Krug RM : Metabolism and expression of RNA polymerase II transcripts in influenza virus infected cells. Mol Cell Biol 1984;4:2198-2206.

22.

Beloso A. , Martínez C. , Valcárcel J. , Fernández-Santarén J. , Ortín J. : Degradation of cellular mRNA during influenza virus infection: its possible role in protein synthesis shutoff. J Gen Virol 1992;73:575-581.

23.

Ortín J. : Multiple levels of posttranscriptional regulation of influenza virus gene expression. Semin Virol 1998;8:335-342.

24.

Falcón AM , Fortes P. , Marión RM , Beloso A. , Ortín J. : Interaction of influenza virus NS1 protein and the human homologue of Staufen in vivo and in vitro. Nucleic Acids Res 1999 ;27:2241-2247.

25.

Fortes P. , Beloso A. , Ortín J. : Influenza virus NS1 protein inhibits premRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J 1994;13:704-712.

26.

Fortes P. , Lamond AI , Ortín J. : Influenza virus NS1 protein alters the subnuclear localization of cellular splicing components. J Gen Virol 1995;76:1001-1007.

27.

De la Luna S. , Fortes P. , Beloso A. , Ortín J. : Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs. J Virol 1995; 69:2427-2433.

28.

Marión RM , Aragón T. , Beloso A. , Nieto A. , Ortín J. : The N-terminal half of the influenza virus NS1 protein is sufficient for nuclear retention of mRNA and enhancement of viral mRNA translation. Nucleic Acids Res 1997;25:4271-4277.

29.

Marión RM , Fortes P. , Beloso A. , Dotti C. , Ortín, J. : A human sequence homologue of Staufen is an RNA-binding protein that is associated with polysomes and localizes to the rough endoplasmic reticulum . Mol Cell Biol 1999;19:2212-2219.

30.

Perales B. , Ortín J. : The influenza A virus PB2 polymerase subunit is required for the replication of viral RNA. J Virol 1997;71:1381-1385.

31.

Zhang J-H. , Chung TDY , Oldenburg KR : A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.

32.

Hamasaki K. , Ueno A. : Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA-protein interactions derived from HIV-1 activators . Bioorg Med Chem Lett 2001;11:591-594.

33.

Lapidot A. , Vijayabaskar V. , Litovchick A. , Yu J. , James TL : Structure-activity relationships of aminoglycoside-arginine conjugates that bind HIV-1 RNAs as determined by fluorescence and NMR spectroscopy. FEBS Lett 2004;577:415-421.

34.

Xiao G. , Kumar A. , Li K. , Rigl CT , Bajic M. , Davis TM , et al: Inhibition of the HIV-1 Rev-RRE complex formation by unfused aromatic cations. Bioorg Med Chem 2001;9:1097-1113.

35.

Chapman RL , Stanley TB , Hazen R. , Garvey EP : Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening. Antiviral Res 2002;54:149-162.

36.

Luedtke NW , Tor Y. : Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 Rev-RRE inhibitors. Biopolymers 2003 ; 70:103-119.

37.

Mills NL , Shelat AA , Guy RK : Assay optimization and screening of RNA-protein interactions by AlphaScreen . J Biomol Screen 2007;12:946-955.

38.

Lipinski CA , Lombardo F. , Dominy BW , Feeney PJ : "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings." Adv Drug Deliv Rev 1997;23:3-25.